NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 17 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to…
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…